Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers

Journal of Clinical Epidemiology

Volumn 65, Issue 9, 2012, Pages 940-945

  Walter, Stephen D ^a   Sun, Xin ^a,b   Heels Ansdell, Diane ^a   Guyatt, Gordon ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Biostatistics; Clinical trials; Methodology; Patient important outcomes; Surrogate markers; Treatment effect

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE;

ARTICLE; BIOSTATISTICS; CALCULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HEPATITIS B; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84864286590     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2012.02.012     Document Type: Article

References (41)

1. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 1989 431 440
2. L.A. Goodman On the exact variance of products J Am Stat Assoc 55 1960 708 713
3. S.M. Lin, M.L. Yu, C.M. Lee, R.N. Chien, I.S. Sheen, and C.M. Chu Interferon therapy in HBeAG positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 2007 45 52
4. M.F. Yuen, C.K. Hui, C.C. Cheng, C.H. Wu, Y.P. Lai, and C.L. Lai Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis b infection: the effect on hepatitis b e antigen seroconversion and the development of cirrhosis-related complications J Hepatol 34 2001 139 145
5. S.W. Schalm, J. Heathcote, J. Cianciara, G. Farrell, M. Sherman, and B. Willems Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial Gut 46 2000 562 568
6. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon alfa-2a, lamivudine, and the combination for HBeAG-positive chronic hepatitis b N Engl J Med 352 2005 2682 2695
7. M.J. Daniels, and M.D. Hughes Meta-analysis for the evaluation of potential surrogate markers Stat Med 16 1996 1965 1982
8. M. Buyse, and G. Molenbergs Criteria for the validation of surrogate endpoints in randomized experiments Biometrics 54 1998 1014 1029
9. M.H. Gail, R. Pfeiffer, H.C. Van Houwelingen, and R.J. Carroll On meta-analytic assessment of surrogate outcomes Biostatistics 1 2000 231 246
10. G. Molenberghs, T. Burzykowski, and A. Alonso A perspective on surrogate endpoints in controlled clinical trials Stat Methods Med Res 13 2004 177 206
11. L. Freedman Quantitative science methods for biomarker validation in chemoprevention trials Cancer Biomark 3 2007 135 140
12. R. Moynihan Surrogates under scrutiny: fallible correlations, fatal consequences BMJ 343 2011 d5160
13. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 1996 605 613
14. J.S. Wolinsky, and C.A. Beck The long march to surrogates of meaningful clinical outcomes in MS trials - are we there yet? Neurology 77 2011 1658
15. M.P. Sormani, L. Bonzano, L. Roccatagliata, G.L. Mancardi, A. Uccelli, and P. Bruzzi Surrogate endpoints for EDSS worsening in multiple sclerosis - a meta-analytic approach Neurology 75 2010 302 309
16. M.E. Ray, K. Bae, M.H.A. Hussain, G.E. Hanks, W.U. Shipley, and H.M. Snadler Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial J Natl Cancer Inst 101 2009 228 236
17. S. Michiels, A. Le Maitre, M. Buyse, T. Burzykowski, E. Maillard, and J. Bogaerts Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data Lancet Oncol 10 2009 341 350
18. L. Chen, and E.E.W. Cohen Surrogate endpoints in head and neck cancer Lancet Oncol 10 2009 309 310
19. M. Buyse, T. Burzykowski, K. Carroll, S. Michiels, D.J. Sargent, and L.L. Miller Progression-free survival is a surrogate for survival in advanced colorectal cancer J Clin Oncol 25 2001 5218 5224
20. M. Buyse Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials Cancer J 15 2009 421 425
21. E.D. Saad, A. Katz, P.M. Hoff, and M. Buyse Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature Ann Oncol 21 2010 7 12
22. M. Buyse, S. Michiels, P. Squifflet, K.J. Lucchesi, K. Hellstrand, and M.L. Brune Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission Haematologica 96 2011 1106 1112
23. A. Pollack, A.L. Hanlon, B. Movsas, G.E. Hanks, R. Uzzo, and E.M. Horwitz Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy Int J Radiat Oncol Biol Phys 57 2003 19 23
24. R.K. Valicenti, M. DeSilvio, G.E. Hanks, A. Porter, H. Brereton, and S.A. Rosenthal Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of radiation therapy oncology group protocol 92-02 Int J Radiat Oncol Biol Phys 66 2006 1064 1071
25. H. Bucher, R. Kunz, D. Cook, A. Holbrook, and G. Guyatt Surrogate outcomes G. Guyatt, D. Rennie, M. Meade, D.J. Cook, Users' guides to the medical literature: a manual for evidence-based clinical practice 2008 McGraw-Hill New York, NY 317 340
26. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary Report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction N Engl J Med 321 1989 406 412
27. The Cardiac Arrhythmia Suppression Trial II (CAST) Investigators Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction N Engl J Med 327 1992 227 233
28. B.M. Psaty, N.S. Weiss, C.D. Furberg, T.D. Koepsell, D.S. Siscovick, and F.R. Rosendaal Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease J Am Med Assoc 282 2007 786 795
29. R. Temple Are surrogate markers adequate to assess cardiovascular disease drugs? J Am Med Assoc 282 1999 790 795
30. M. Domanski, S. Pocock, C. Bernaud, J. Borer, N. Geller, and J. Revkin Surrogate endpoints in randomized cardiovascular clinical trials Fundam Clin Pharmacol 25 2011 411 413
31. K.R. Johnson Strengths and weaknesses of renal markers as risk factors and surrogate markers Kidney Int 79 2011 1272 1274
32. T. Burzykowski, M. Buyse, M.J. Piccart-Gebhard, G. Sledge, J. Carmichael, and H.-J. Lück Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer J Clin Oncol 26 2008 987 992
33. R.A. Mishkad, V. Zietemann, R. Gothe, R. Schwarzer, A. Conrads-Frank, and P. Schnell-Inderst Progression-free survival as a surrogate endpoint in advanced breast cancer Int J Technol Assess Health Care 24 2008 371 383
34. M.M. Joffee, and T. Greene Related causal frameworks for surrogate outcomes Biometrics 65 2008 530 538
35. A. Schatzkin, M. Gail, and L. Freedman The promise and peril of surrogate endpoints in cancer research T. Burzykowski, G. Molenberghs, M. Buyse, The evaluation of surrogate endpoints 2005 Springer New York, NY 349 366
36. G. Molenbergh, M. Buyse, and T. Burzykowski The history of surrogate endpoint validation T. Burzykowski, G. Molenberghs, M. Buyse, The evaluation of surrogate endpoints 2005 Springer New York, NY 67 82
37. V.G. De Gruttola, P. Clax, D.L. DeMets, G.J. Downing, S.S. Ellenberg, and L. Friedman Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop Control Clin Trials 22 2001 485 502
38. Z. Wu, P. He, and G. Zhi Sufficient conditions for concluding surrogacy based on observed data Stat Med 30 2010 2422 2434
39. T. Burzykowski, and M. Buyse Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation Pharm Stat 5 2006 1973 1986
40. S.G. Baker, D.J. Sargent, M. Buyse, and T. Burzykowski Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time Biometrics 68 2012 248 257 10.1111/j.1541-0420.2011.01646.x
41. A. Schatzkin Intermediate markers as surrogate endpoints in cancer research Hematol Oncol Clin North Am 14 2000 887 905